logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Keryx Biopharmaceuticals (KERX) Spikes on Upgrade from Roth Capital

By  +Follow October 16, 2013 9:45AM
Share:
Tickers Mentioned:

Shares in Keryx Pharmaceuticals (KERX) joined the market rally on Wednesday with gusto, climbing nearly 20 percent on news that it was being upgraded by several analysts. Keryx has been experiencing a strong year since getting back solid data from a Phase III trial on its phosphate-binder Zerenex, which is intended for use by dialysis patients.

Upgrades from Roth Capital, Maxim Group

Keryx's Wednesday bounce can be attributed to a bullish recommendation from Dr. Joseph Pantginis at Roth Capital, who reiterated his buy rating while raising his price target from $16 to $24. In a September 24 interview with Seeking Alpha’s Ben Yoffe, Pantginis cited the 52 percent reduction in IV iron use by patients in the Phase III clinical study as being an important factor.

“We believe the ‘iron sparing’ component of Zerenex' profile will differentiate the drug upon anticipated approval,” he said. “We believe that not enough emphasis is currently being placed by the street on the iron sparing parameters seen to date, especially in the Phase III. The pharmacoeconomic benefit that can be seen using Zerenex can easily reach hundreds of millions of dollars with reduced iv iron and ESA use such as Epogen.”

Issuing a much more bearish, but nonetheless positive, outlook on August 1 were Maxim Group analysts, who upgraded the stock to a buy and raised the price target from $9 to $12.

Zerenex Approval by FDA Continues Strong Year

News of the positive Phase III study results initially caused Keryx’s stock to more than triple from January 18 to January 30 of this year. So far, the stock’s up nearly 300 percent on the year. The most recent increase also comes on the heels of news that the New Drug Application (NDA) for Zerenex had been approved by the FDA on Tuesday of last week.

"We are very pleased with the FDA's acceptance for filing of our NDA for Zerenex, as this represents an important achievement in the development of Zerenex,” said CEO Ron Bentsur at the time. “We believe that Zerenex has the potential to make a meaningful difference in the lives of patients with chronic kidney disease on dialysis, and we look forward to continuing to work with the FDA in its review process of the Zerenex NDA."

Results for KERX
Stockaholics
18 Apr 14 20:10:48
Our Penny Stock Picks gained 5,000% in 4 months! Get the next Pick Early: http://t.co/5B5saivZk0 $YPF $KERX $ATSG
Stockaholics
18 Apr 14 17:29:48
Our Penny Stock Picks gained 5,000% in 4 months! Get the next Pick Early: http://t.co/5B5saivZk0 $YPF $KERX $ATSG
John Paul Montana
18 Apr 14 15:43:31
@danravicher you're wrong about $kerx
John Paul Montana
18 Apr 14 15:43:03
@danravicher Scott insinuates you're pumping $kerx, says you're far more educated in the field, but insists his street smarts tell him
Stockaholics
18 Apr 14 10:56:41
Members saw 5,000% gains on Penny Stock Alert's in 4 months! Subscribe Today: http://t.co/5B5saivZk0 $YPF $KERX $ATSG
Stockaholics
18 Apr 14 10:37:35
Members saw 5,000% gains on Penny Stock Alert's in 4 months! Subscribe Today: http://t.co/5B5saivZk0 $TSL $KERX $GGAL
Stock_Tracker
18 Apr 14 08:39:25
Keryx Biopharmaceuticals (KERX) 13.46 $KERX Keryx Biopharmaceuticals Strengthens Leadership Team With Key Addi http://t.co/jm2csmx6uo
BV Healthcare
18 Apr 14 07:41:26
$KERX Keryx Biopharmaceuticals Strengthens Leadership Team With Key Additions in S.. http://t.co/vxVXAIP9dY
StockMatusow
17 Apr 14 12:51:14
@DIRTY__CARL cost of revenue, and other factors tell me $KERX should not have a valuation over $500M, currently at 1.3B, it more than
StockMatusow
17 Apr 14 12:46:59
@DIRTY__CARL i rarely hold any decent size positions over night, U are a long term "investor" in $KERX, if u are right, what do you
StockMatusow
17 Apr 14 12:45:29
@DIRTY__CARL and one more answer -- suckers by gap ups, why would i short $KERX into PDUFA when im confident Zerenex will be approved?
StockMatusow
17 Apr 14 12:38:04
maybe this will be the first time? and I currently have NO POSITION in $KERX, not trading today, taking day off
StockMatusow
17 Apr 14 12:36:37
now, $KERX could get acquired, but by whom? Generic Phos binders more and more
StockMatusow
17 Apr 14 12:36:00
$KERX valuation should be somewhere around $400M << think otherwise? cool with me, check my record
StockMatusow
17 Apr 14 12:35:10
so the company might net $20M a year from it, and since no other pipeline $KERX
StockMatusow
17 Apr 14 12:34:40
so then $KERX can receive royalties on a product they dont even own and pay royalties
StockMatusow
17 Apr 14 12:34:14
$KERX longs cracking? don't worry, Zerenex is likely to be approved, and company could get a royalty deal
StockMatusow
17 Apr 14 12:32:41
@DIRTY__CARL @danravicher not what i said at all. he created the buzz relating the bill to $KERX. he should be more concerned with company
StockMatusow
17 Apr 14 12:31:54
@DIRTY__CARL @danravicher was all over the internet, meanwhile, your $KERX is going down, down, as it should = valuation, not cult love fest
Justin Burkhardt
17 Apr 14 10:15:52
sold 50 $KERX April 19 15$ puts at 1.45 from .50
trader j
17 Apr 14 06:39:48
RT @danravicher: @StockMatusow I didn't know $AMRN has strong Phase III data, a PDUFA date, and a robust patent portfolio like $KERX.
Damien S. Faucher
17 Apr 14 04:14:05
$KERX Keryx Biopharmaceuticals: Is The High Valuation Justified? http://t.co/rR8B3GrwzB
Federico
16 Apr 14 22:33:01
RT @TomSilver39: $KERX JMP;TP=$25 Impax Authorized Generic for Renvela Should Not Ruin Sales Potential for Zerenex http://t.co/gpbfIr6A1T
DIRTY CARL
16 Apr 14 22:10:32
@StockMatusow $KERX Answer one simple question Scott. ARE YOU SO CONFIDENT IN YOUR SHORT THESIS THAT YOU WILL SHORT KERX INTO PDUFA?
DIRTY CARL
16 Apr 14 21:57:11
@StockMatusow @danravicher Scott, I love your theory that Ron created a bill of congress(which passed) to help the company. $KERX
DIRTY CARL
16 Apr 14 21:48:35
@danravicher Scott doesn't shut up. He asked for proof that the last offering was a secondary. I provided him the link. He still lies. $KERX
Joe
16 Apr 14 18:27:17
@ChetStedman5 You may be right? 1 drug pony; NCE issues; analysts love it: avg PT: $26; >$1B MC. Where have I seen this b4? $kerx
John Paul Montana
16 Apr 14 17:20:27
RT @TomSilver39: $KERX JMP;TP=$25 Impax Authorized Generic for Renvela Should Not Ruin Sales Potential for Zerenex http://t.co/gpbfIr6A1T
Randy
16 Apr 14 16:23:06
I see and get the dislike for $kerx. I will be short again sometime in the future. It's not ready imo. Let it have it's PDUFA and get appr.
Ivor O'Shea
16 Apr 14 16:09:23
RT @TomSilver39: $KERX JMP;TP=$25 Impax Authorized Generic for Renvela Should Not Ruin Sales Potential for Zerenex http://t.co/gpbfIr6A1T
Tom Silver
16 Apr 14 15:17:03
$KERX JMP;TP=$25 Impax Authorized Generic for Renvela Should Not Ruin Sales Potential for Zerenex http://t.co/gpbfIr6A1T
StockMatusow
16 Apr 14 13:47:48
@TravisMKnight since i will likely never go long on $KERX again but for a scalp, I will wait until it really becomes a bloated pig
StockMatusow
16 Apr 14 13:45:26
@TravisMKnight i will prob stop shorting $KERX, im up over 16k doing it, I will wait until Zerenex gets approved then slam 50k short
StockMatusow
16 Apr 14 13:44:19
@TravisMKnight hence, tons of short covering today, light volume = manipulation, but trade price, $KERX on news today should have been
StockMatusow
16 Apr 14 11:23:55
$KERX going under $13.50, likely today, let's see if I'm right! #trading #stocks #biotech #short #nasdaq #ibb #dow #nyse $SPY
mmk
16 Apr 14 08:47:08
RT @stocknews77: $KERX - Keryx Biopharmaceuticals: Is The High Valuation Justified? -> http://t.co/w6EIDTs7vn #stock #stocks #stockaction
StockMatusow
16 Apr 14 08:47:07
Keryx Biopharmaceuticals: Is The High Valuation Justified? - Seeking Alpha http://t.co/VMZOOTyQvC $KERX #biotech #short #nasdaq #ibb
StockMatusow
16 Apr 14 08:43:42
@danravicher at any point, and this is where you $KERX fans just fail to get it. it comes down to business
LoveStockNews
16 Apr 14 08:42:03
$KERX - Keryx Biopharmaceuticals: Is The High Valuation Justified? -> http://t.co/w6EIDTs7vn #stock #stocks #stockaction
StockMatusow
16 Apr 14 08:40:07
@danravicher investing in a company on pure speculation is foolish, these are not investments at all, now if $KERX actually had
StockMatusow
16 Apr 14 08:37:25
@danravicher $KERX only "pumped" up because Ron engaged in "promotion" designed to help get out takers of the offering underwater
Daniel B. Ravicher
16 Apr 14 08:29:07
@StockMatusow I didn't know $AMRN has strong Phase III data, a PDUFA date, and a robust patent portfolio like $KERX.
Daniel B. Ravicher
16 Apr 14 08:18:40
@StockMatusow As for Zerenex not sailing through its June PDUFA date, good luck with that. They're golden. $KERX Pls try some new short arg.
Daniel B. Ravicher
16 Apr 14 08:17:43
@StockMatusow You just don't listen, do you? I already said, 18 times, $KERX has no sales force bc it will be bought out. Why hire to fire?
StockMatusow
16 Apr 14 08:12:38
@danravicher why doesnt $KERX have a sales force now so close to PDUFA? Also, no drug is ever "guaranteed" to be FDA approved
Blair Jensen
16 Apr 14 08:10:43
Most bearish stocks on Twitter: $bbby $ccl $cog $fdo $gm $gmcr $gs $hlf $ibb $isrg $kerx $m $nadq $xone $yy http://t.co/4eRClglUOH
Daniel B. Ravicher
16 Apr 14 08:09:06
@StockMatusow Zerenex is a small molecule drug, not a biologic. I'm done debating a non-doctor non-patent attorney short. Good luck. $KERX
Daniel B. Ravicher
16 Apr 14 08:07:56
@StockMatusow So you're short $KERX and your entire thesis is based on one insider selling and your own personal medical opinion? Weak.
Daniel B. Ravicher
16 Apr 14 08:05:41
@StockMatusow @chasingthealpha @Gekkowire They can't sell "something close" because their drugs are not. Plus, $KERX has patents.
Daniel B. Ravicher
16 Apr 14 08:04:54
@StockMatusow One insider selling $KERX is your strongest argument? Then short $FB, bc Sandberg is puking its shares. Weak sauce.
				
				
By  +Follow October 16, 2013 9:45AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.